# Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

> **NCT00856206** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1315 (actual)

## Conditions studied

- Gout

## Interventions

- **BIOLOGICAL:** Rilonacept
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00856206
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 1315 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856206, "Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00856206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*